AIM Concept Integration
3rd Year MBBS
Blood and Immunology
3rd Year MBBS
Blood and Immunology
Hypersensitivity, Immune Tolerance, Autoimmunity, Immunodeficiency and Immunomodulatory Drugs
Connect the major immune mechanisms, disease consequences and therapeutic targets in one rapid-revision view.
1. THE TOPIC IN ONE CONNECTED FLOW
Normal immunity requires an effective response against foreign antigens together with tolerance to self. Disease appears when immune activity becomes excessive, is directed against self, fails to protect the host, or reacts against transplanted tissue. Immunomodulating drugs act at different points in these pathways to suppress harmful immunity or strengthen selected immune responses.
Normal Immune Balance
Protective immunity + self-tolerance
→
Immune Dysregulation
Excess response, loss of tolerance, immune failure or allorecognition
→
Pathological Pathways
Hypersensitivity • autoimmunity • graft reaction • immunodeficiency
→
Functional Consequence
Inflammation, tissue injury, graft dysfunction or impaired host defense
→
Clinical Expression
Allergy, autoimmune disease, transplant rejection, opportunistic infection
→
Therapeutic Modulation
Suppress damaging pathways or stimulate useful immunity
Excess or misdirected immunity
Allergen / tissue antigen / self-antigen
→
antibody or T-cell activation
→
inflammatory or functional tissue injury
→
antibody or T-cell activation
→
inflammatory or functional tissue injury
Failure of protective immunity
Congenital defect or acquired cause such as HIV
→
loss of immune function
→
recurrent or opportunistic infection
→
loss of immune function
→
recurrent or opportunistic infection
2. KEY CLINICAL CONNECTIONS
Hypersensitivity Pattern
Allergen re-exposure
→
IgE cross-linking on mast cells
→
rapid mediator release
→
immediate allergy or anaphylaxis
→
IgE cross-linking on mast cells
→
rapid mediator release
→
immediate allergy or anaphylaxis
Sensitized T cells
→
cytokine-driven inflammation
→
delayed hypersensitivity
→
cytokine-driven inflammation
→
delayed hypersensitivity
Transplantation Pattern
Recipient immunity recognizes donor antigens
→
cellular or antibody injury
→
graft dysfunction
→
cellular or antibody injury
→
graft dysfunction
Donor T cells attack recipient tissues
→
skin, gut and liver injury
→
GVHD
→
skin, gut and liver injury
→
GVHD
Immunomodulation Pattern
Calcineurin inhibitors
→
reduced IL-2 transcription
→
reduced T-cell activation
→
reduced IL-2 transcription
→
reduced T-cell activation
Targeted antibodies / immunostimulants
→
modify selected immune pathways
→
autoimmune or antitumor benefit
→
modify selected immune pathways
→
autoimmune or antitumor benefit
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ Type I hypersensitivity:
IgE on mast cells → mediator release → rapid allergic manifestations; later cytokine-driven eosinophilic inflammation can prolong the response.
IgE on mast cells → mediator release → rapid allergic manifestations; later cytokine-driven eosinophilic inflammation can prolong the response.
Type II versus Type III:
antibody against fixed cell or tissue antigen → type II injury, whereas circulating immune complexes → deposition and complement-mediated type III inflammation.
antibody against fixed cell or tissue antigen → type II injury, whereas circulating immune complexes → deposition and complement-mediated type III inflammation.
⭐ Self-tolerance:
central deletion / receptor editing plus peripheral anergy and regulatory T-cell suppression → control of autoreactive lymphocytes → prevention of autoimmunity.
central deletion / receptor editing plus peripheral anergy and regulatory T-cell suppression → control of autoreactive lymphocytes → prevention of autoimmunity.
Autoimmune disease:
genetic susceptibility + environmental or tissue trigger → loss of self-tolerance → autoantibody- or T-cell-mediated tissue injury.
genetic susceptibility + environmental or tissue trigger → loss of self-tolerance → autoantibody- or T-cell-mediated tissue injury.
⭐ Transplant rejection:
pre-existing antibody → hyperacute thrombosis; activated cellular/antibody responses → acute rejection; persistent vascular injury → chronic narrowing and fibrosis.
pre-existing antibody → hyperacute thrombosis; activated cellular/antibody responses → acute rejection; persistent vascular injury → chronic narrowing and fibrosis.
Immunodeficiency:
B-cell, T-cell, combined, phagocyte or complement defect → impaired host defense; HIV adds acquired progressive CD4-positive T-cell dysfunction and loss.
B-cell, T-cell, combined, phagocyte or complement defect → impaired host defense; HIV adds acquired progressive CD4-positive T-cell dysfunction and loss.
Immunosuppressive drugs:
corticosteroids reduce inflammatory gene expression; cyclosporine/tacrolimus inhibit calcineurin; sirolimus inhibits mTOR; mycophenolate limits nucleotide synthesis → reduced lymphocyte activity.
corticosteroids reduce inflammatory gene expression; cyclosporine/tacrolimus inhibit calcineurin; sirolimus inhibits mTOR; mycophenolate limits nucleotide synthesis → reduced lymphocyte activity.
⭐ Targeted immunomodulation:
antibodies can deplete cells or block cytokine/receptor pathways, while checkpoint inhibition or selected cytokines stimulate immunity → therapeutic benefit with risk of infection or immune-mediated toxicity.
antibodies can deplete cells or block cytokine/receptor pathways, while checkpoint inhibition or selected cytokines stimulate immunity → therapeutic benefit with risk of infection or immune-mediated toxicity.
AIM Exam Trap:
Graft rejection means recipient immunity attacks the graft, whereas graft-versus-host disease means donor immune cells attack the recipient.
Graft rejection means recipient immunity attacks the graft, whereas graft-versus-host disease means donor immune cells attack the recipient.